Clexio is a clinical-stage company designing novel drugs based on validated Mechanisms of Action in NeuroPsychiatry.
We are developing innovative therapies to address patients’ unmet needs in Major Depressive Disorder, Schizophrenia and Bipolar Depression.
Our lead drug candidate (CLE-100) is currently being tested in Phase 2 multicenter studies in the United States.
Our lead preclinical candidate (CLE-905) is undergoing IND-enabling activities, with a First-In-Human Phase 1 study expected to start in the coming months.
Our multidisciplinary team brings years of experience in the Pharmaceutical and Biotech industries and encompasses end-to-end drug development expertise, from early stage to advanced clinical stages, and regulatory approvals.
Individually and as a team, we are excited every day to use our expertise to innovate, integrate, apply, and develop new and effective solutions for patients.
